Table 1.
Cohort characteristics.
| Characteristic | BRCA cases (N = 75) | Matched Controls (N = 150) | Chi-square | ||
|---|---|---|---|---|---|
| No. | % | No. | % | p-value | |
| Planned arm1 | 1.00 | ||||
| A | 39 | 52.0 | 78 | 52.0 | |
| B | 18 | 24.0 | 36 | 24.0 | |
| C | 18 | 24.0 | 36 | 24.0 | |
| Lymph node stage1 | 1.00 | ||||
| N0 | 41 | 54.7 | 82 | 54.7 | |
| N1-2 | 34 | 45.3 | 68 | 45.3 | |
| Age range1 (years) | 1.00 | ||||
| Under 40 | 35 | 46.7 | 70 | 46.7 | |
| 41–50 | 21 | 28.0 | 42 | 28.0 | |
| 51–60 | 15 | 20.0 | 30 | 20.0 | |
| 61–70 | 4 | 5.3 | 8 | 5.3 | |
| Planned administration schedule | 0.57 | ||||
| Every 2 weeks | 38 | 50.7 | 82 | 54.7 | |
| Every 3 weeks | 37 | 49.3 | 68 | 45.3 | |
| ECOG status at baseline | 0.63 | ||||
| 0 | 69 | 92.0 | 135 | 90.0 | |
| 1 | 6 | 8.0 | 15 | 10.0 | |
| PAM50 subtype | 0.29 | ||||
| Basal | 61 | 81.3 | 130 | 86.7 | |
| Nonbasal | 14 | 18.7 | 20 | 13.3 | |
| TNBC subtype | 0.90 | ||||
| BL1 | 18 | 24.0 | 29 | 19.3 | |
| BL2 | 3 | 4.0 | 8 | 5.3 | |
| IM | 14 | 18.7 | 35 | 23.3 | |
| LAR | 2 | 2.7 | 8 | 5.3 | |
| M | 17 | 22.7 | 30 | 20.0 | |
| MSL | 8 | 10.7 | 16 | 10.7 | |
| UNS | 13 | 17.3 | 24 | 16.0 | |
| Pathologic response | 0.78 | ||||
| Residual disease | 34 | 45.3 | 71 | 47.3 | |
| Complete response (pCR) | 41 | 54.7 | 79 | 52.7 |
1Planned arm, lymph node stage, and age range were used to match controls to cases (2:1).
ECOG Eastern Cooperative Oncology Group, No. number, pCR pathologic complete response, TNBC triple-negative breast cancer, BL1 basal-like 1, BL2 basal-like 2, IM immunomodulatory, LAR luminal androgen receptor, M mesenchymal, MSL mesenchymal stem-like, UNS unselected.